No.  | API Product  | CAS No  | DMF/CEP  | Standard  | Indication  | 
1  | Benazepril HCl  | 86541-74-4  | NMPA DMF: Y20190002852 DMF: 033744 CEP:2015-322 CDSCO RC/BD-002644  | USP/EP/Ch.P.  | Cardiovascular  | 
2  | Tirofiban HCl  | 150915-40-5  | NMPA DMF: Y20190006974 DMF: 032701 EU/ASMF/00701  | In-house  | Cardiovascular  | 
3  | Dronedarone HCl  | 141625-93-6  | NMPA DMF:Y20220000297 DMF: 037247 CEP: 2022-277  | USP/EP/Ch.P.  | Cardiovascular  | 
4  | Eribulin Mesylate  | 441045-17-6  | DMF:035523 EU/ASMF/00569  | JP  | Anti-Cancer  | 
5  | Ibrutinib(Form A&C)  | 936563-96-1  | NMPA DMF: Y20230000804 DMF:038919 DMF:031917  | In-house  | Anti-Cancer  | 
6  | Alogliptin Benzoate  | 850649-62-6  | NMPA DMF: Y20230001355 DMF:039984  | In-house  | Diabetes  | 
7  | Fosaprepitant Dimeglumine  | 265121-04-8  | NMPA DMF: Y20200001493 DMF:035766 JP MF:304MF10040  | In-house  | Anti-Cancer  | 
8  | Aprepitant  | 170729-80-3  | NMPA DMF: Y20200000221 DMF:033175 CEP:2019-117 JP MF:230MF10074  | USP/EP  | Anti-Cancer  | 
9  | Dapagliflozin  | 960404-48-2  | NMPA DMF: Y20220000848  | In-house  | Diabetes  | 
10  | Entecavir  | 209216-23-9  | NMPA DMF: Y20170000425 DMF:033104 CEP:2018-006  | EP/USP  | Anti-Virus  | 
11  | Gefitinib  | 184475-35-2  | NMPA DMF: Y20200001369 CEP: 2022-291  | EP  | Anti-Cancer  | 
12  | Linagliptin  | 668270-12-0  | DMF:031294  | In-house  | Diabetes  | 
13  | Fasudil HCl  | 105628-07-7  | NMPA DMF: Y20220000495 JP MF:231MF10048  | Ch.P./JP  | Cardiovascular  | 
14  | Flurbiprofen Axetil  | 91503-79-6  | NMPA DMF: Y20220000095  | In-house  | Analgesic  | 
No.  | API Product  | CAS No  | DMF/CEP  | Standard  | Indication  | 
15  | Difelikefalin Acetate  | 1024829-44-4  | Validated  | In-house  | Antipruritic  | 
16  | Linaclotide  | 851199-59-2  | In progress  | In-house  | IBS-C  | 
17  | Tirzepatide  | 2023788-19-2  | In progress  | In-house  | Diabetes  | 
18  | Etelcalcetide HCl  | 1334237-71-6  | In progress  | In-house  | SHPT  | 
19  | Semaglutide  | 910463-68-2  | In progress  | In-house  | Diabetes  | 
No.  | API Product  | CAS No  | DMF/CEP  | Standard  | Indication  | 
20  | Trabectedin  | 114899-77-3  | In progress  | In-house  | Anti-Cancer  | 
21  | Lurbinectedin  | 497871-47-3  | DMF:037624  | In-house  | Anti-Cancer  | 
22  | Baricitinib  | 1187594-09-7  | DMF:036732  | In-house  | Rheumatoid Arthritis  | 
23  | Carfilzomib  | 868540-17-4  | In progress  | In-house  | Anti-Cancer  | 
24  | Pralsetinib  | 2097132-94-8  | In progress  | In-house  | Anti-Cancer  | 
25  | Exatecan Mesylate  | 169869-90-3  | In progress  | In-house  | Anti-Cancer  | 
26  | Landiolol HCl  | 144481-98-1  | In progress  | In-house  | Cardiovascular  | 
27  | Pentoxifylline  | 6493-05-6  | In progress  | In-house  | Cardiovascular  | 
28  | Ozanimod HCl  | 1618636-37-5  | In progress  | In-house  | Multiple Sclerosis  | 
29  | Enoxaparin Sodium  | 679809-58-6  | In progress  | In-house  | Cardiovascular  | 
30  | Dalteparin Sodium  | 9041-08-1  | In progress  | In-house  | Cardiovascular  | 
31  | Nadroparin Calcium  | 37270-89-6  | In progress  | In-house  | Cardiovascular  | 
32  | Parnaparin Sodium  | 9041-08-1  | In progress  | In-house  | Cardiovascular  | 
33  | Reviparin sodium  | 9005-49-6  | In progress  | In-house  | Cardiovascular  | 
34  | Bemiparin Sodium  | 9041-08-1  | In progress  | In-house  | Cardiovascular  | 
35  | Fondaparinux Sodium  | 114870-03-0  | DMF:037499  | In-house  | Cardiovascular  |